US2011262385A1PendingUtilityA1

Use of interleukin-22 in the treatment of fatty liver disease

57
Assignee: HUANG YU LIANGPriority: Aug 6, 2007Filed: Aug 1, 2008Published: Oct 27, 2011
Est. expiryAug 6, 2027(~1 yrs left)· nominal 20-yr term from priority
Inventors:Yu-Liang HuangZhi Hua HuangQi Sun
A61P 43/00A61P 3/06A61K 38/20A61P 1/16
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.

Claims

exact text as granted — not AI-modified
1 . A method for treatment of fatty liver, said method comprises administering to a subject in need of treatment a composition, said composition comprises a pharmaceutically effective amount of IL-22. 
     
     
         2 . Use of IL-22 in manufacture of a composition for treating fatty liver. 
     
     
         3 . Use of IL-22 in manufacture of a medicament for treating fatty liver. 
     
     
         4 . The use according to  claim 2 , wherein said IL-22 is used for reducing steatosis. 
     
     
         5 . The use according to  claim 2 , wherein said IL-22 is used for decreasing serum triglyceride level. 
     
     
         6 . The use according to  claim 2 , wherein said IL-22 is used for decreasing transaminase level. 
     
     
         7 . The use according to  claim 2 , wherein said IL-22 is human IL-22 
     
     
         8 . The use according to  claim 2 , wherein said IL-22 is encoded by the polynucleotide of SEQ ID NO.1. 
     
     
         9 . The use according to  claim 2 , wherein said fatty liver is alcoholic fatty liver or non-alcoholic fatty liver. 
     
     
         10 . The use according to  claim 3 , wherein said IL-22 is used for reducing steatosis. 
     
     
         11 . The use according to  claim 3 , wherein said IL-22 is used for decreasing serum triglyceride level. 
     
     
         12 . The use according to  claim 3 , wherein said IL-22 is used for decreasing transaminase level. 
     
     
         13 . The use according to  claim 3 , wherein said IL-22 is human IL-22. 
     
     
         14 . The use according to  claim 3 , wherein said IL-22 is encoded by the polynucleotide of SEQ ID NO.1. 
     
     
         15 . The use according to  claim 3 , wherein said fatty liver is alcoholic fatty liver or non-alcoholic fatty liver.

Join the waitlist — get patent alerts

Track US2011262385A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.